Articles by Cynthia X. Ma, MD, PhD
77 Updated Efficacy of Mutant-Selective PI3Kα Inhibitor Zovegalisib (RLY-2608) in Combination With Fulvestrant in Patients With PIK3CA-Mutant HR+/HER2– Advanced Breast Cancer: ReDiscover Trial
BySarah L. Sammons,Cristina Saura,Antoine Italiano,Alison Schram, MD,Pablo Tolosa,Anne F. Schott, MD,Á. Guerrero-Zotano,Santiago Ponce-Aix,Rita Nanda, MD,Kari B. Wisinski, MD,Jennifer Segar,Mei Wei,Jia (Jenny) Liu,Alexander Spira, MD, PhD, FACP, FASCO,Julia E. McGuinness, MD,Jordi Rodón,Cynthia X. Ma, MD, PhD,Milana Bergamino,Giuseppe Curigliano,Andreas Varkaris Zovegalisib plus fulvestrant demonstrated an objective response rate of 38.7% and a median progression-free survival of 10.3 months in PIK3CA-mutant HR+/HER2– advanced breast cancer in the ReDiscover trial.
80 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as First-Line (1L) Treatment (tx) for Unresectable Locally Advanced/Metastatic Triple-Negative Breast Cancer (a/mTNBC): Final Results From the Phase 1b/2 BEGONIA Study
ByPeter Schmid, MD,Hwei-Chung Wang,Filipa Lynce,Yeon Hee Park,Cynthia X. Ma, MD, PhD,Kyung Hae Jung,Shin-Cheh Chen,Ming-Feng Hou,Catherine Prady,Ling-Ming Tseng,Jamil Asselah,Piotr J. Wysocki,Simon Lord,Purnima Rao-Melacini,Ross Stewart,Karola Warzyszyńska,Petra Vuković,Seock-Ah Im Dato-DXd plus durvalumab demonstrated robust antitumor activity as first-line treatment for advanced/metastatic triple-negative breast cancer in the phase 1b/2 BEGONIA study, with manageable safety.
107 Updated Results and an Exploratory Analysis of ESR1 Mutations (ESR1m) Circulating Tumor DNA (ctDNA) Dynamics From SERENA-6, a Phase III Trial of Camizestrant + CDK4/6 Inhibitor (CDK4/6i) for Emergent ESR1m During First-Line (1L) Endocrine-Based Therapy and Ahead of Disease Progression in Patients With HR+/HER2– Advanced Breast Cancer (ABC)
ByAdam M. Brufsky, MD, PhD,François-Clément Bidard,Erica L. Mayer, MD, MPH,Yeon Hee Park,Wolfgang Janni,Cynthia X. Ma, MD, PhD,Massimo Cristofanilli, MD,Giampaolo Bianchini,Kevin Kalinsky, MD, MS,Hiroji Iwata,Stephen Chia,Peter A. Fasching,Zbigniew Nowecki,Javier Pascual,Einav Nili Gal-Yam,Wei-Pang Chung,Seock-Ah Im,Alberto Zambelli,Florence Dalenc,Mafalda Oliveira,Steven Fox,Manuel Selvi Miralles,Christopher Morrow,Cynthia Huang Bartlett,Nicholas C. Turner, MD 
16 Open-Label, Randomized, Multicenter, Phase 3, ELAINE 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating ER+/HER2–, Locally Advanced or Metastatic Breast Cancer With an ESR1 Mutation
ByMatthew P. Goetz, MD,Seth A. Wander,Thomas Bachelot,Gerald Batist,Javier Cortés, MD,Massimo Cristofanilli, MD,Giuseppe Curigliano,Alexandre de Nonneville,Einav Nili Gal-Yam,Komal Jhaveri,Cynthia X. Ma, MD, PhD,Heather A. Parsons, MD, MPH,Hope S. Rugo, MD,Sarah L. Sammons,Daniel G. Stover,Chris Twelves, MD, FRCP,Aditya Bardia, MD, MPH, FASCO,Paul V. Plourde,David J. Portman,Senthil Damodaran 22 Updated Results From VERITAC Evaluating Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer
BySara A. Hurvitz, MD,Anne F. Schott, MD,Cynthia X. Ma, MD, PhD,Rita Nanda, MD,George Zahrah,Natasha Hunter, MD,Antoinette R. Tan,Melinda L. Telli, MD,Jesus Anampa Mesias,Rinath M. Jeselsohn,Pamela N. Munster, MD,Eric Zhi,Elizabeth Duperret,Cecile Mather,Erika P. Hamilton, MD,Hyo S Han 
24 ARV-471, a PROTAC Estrogen Receptor (ER) Degrader in Advanced ER+/Human Epidermal Growth Factor Receptor 2 (HER2)– Breast Cancer: Phase 2 Expansion (VERITAC) of a Phase 1/2 Study
BySara A. Hurvitz, MD,Anne F. Schott, MD,Cynthia X. Ma, MD, PhD,Erika P. Hamilton, MD,Rita Nanda, MD,George Zahrah,Natasha Hunter, MD,Antoinette R. Tan,Melinda L. Telli, MD,Jesus Anampa Mesias,Rinath Jeselsohn,Pamela N. Munster, MD,Haolan Lu,Richard Gedrich,Cecile Mather,Janaki Parameswaran,Hyo S Han 
Cynthia Ma, MD, PhD, explains key efficacy findings regarding HER-targeted therapy to treat patients with HER2-mutant breast cancer.
An expert in treating breast cancer discusses potential therapy options for patients with HER2-mutant.
CancerNetwork® spoke with Cynthia X. Ma, MD, PhD, of Washington University School of Medicine in St. Louis, following the American Association for Cancer Research Annual Meeting 2021 about the benefits of the meeting to clinical trial investigators.
CancerNetwork® spoke with Cynthia X. Ma, MD, PhD, during the American Association for Cancer Research Annual Meeting 2021 about data supporting the potential use of the exemestane/leuprolide acetate plus pembrolizumab combination.
This article aims to provide an overview of The Cancer Genome Atlas findings, with a particular focus on their potential biological relevance and therapeutic implications.
It is time to develop more active treatments in the early-disease setting that actually eradicate ER-positive breast cancer before new mutations and secondary resistance have a chance to develop. In this regard, standard chemotherapy is not the answer.
Poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitors are designed to exploit the “synthetic lethality” concept for cancer therapy.
This article reviews ongoing progress in the effort to identify predictors of endocrine therapy responsiveness for breast cancer and discusses the value of “pre-treatment” vs “on-treatment” tumor profiling for predicting outcomes.
